BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11377178)

  • 1. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
    Yoneda F; Moto T; Sakae M; Ohde H; Knoll B; Miklya I; Knoll J
    Bioorg Med Chem; 2001 May; 9(5):1197-212. PubMed ID: 11377178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
    Knoll J; Yoneda F; Knoll B; Ohde H; Miklya I
    Br J Pharmacol; 1999 Dec; 128(8):1723-32. PubMed ID: 10588928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
    Miklya I
    Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of the catecholaminergic and serotoninergic neurons in the rat brain by R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, (-)-BPAP.
    Knoll J; Miklya I; Knoll B
    Life Sci; 2002 Sep; 71(18):2137-44. PubMed ID: 12204771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged.
    Knoll J; Miklya I; Knoll B; Yasusa T; Shimazu S; Yoneda F
    Life Sci; 2002 Sep; 71(17):1975-84. PubMed ID: 12175892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
    Miklya I
    Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
    Gaszner P; Miklya I
    Neuropsychopharmacol Hung; 2004 Dec; 6(4):210-20. PubMed ID: 15825677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
    Miklya I; Knoll J
    Life Sci; 2003 May; 72(25):2915-21. PubMed ID: 12697274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
    Gaszner P; Miklya I
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):5-14. PubMed ID: 16023777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons.
    Knoll J; Miklya I; Knoll B; Markó R; Kelemen K
    Life Sci; 1996; 58(10):817-27. PubMed ID: 8602114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain.
    Knoll J; Baghy K; Eckhardt S; Ferdinandy P; Garami M; Harsing LG; Hauser P; Mervai Z; Pocza T; Schaff Z; Schuler D; Miklya I
    Life Sci; 2017 Aug; 182():57-64. PubMed ID: 28623006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain.
    Knoll J; Miklya I; Knoll B; Markó R; Rácz D
    Life Sci; 1996; 58(23):2101-14. PubMed ID: 8649195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes.
    Shimazu S; Tanigawa A; Sato N; Yoneda F; Hayashi K; Knoll J
    Life Sci; 2003 May; 72(24):2785-92. PubMed ID: 12679194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fate of (-)1-(benzofuran-2-yl)-2-propylaminopentane . HCl, (-)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain.
    Magyar K; Lengyel J; Bolehovszky A; Knoll B; Miklya I; Knoll J
    Eur J Drug Metab Pharmacokinet; 2002; 27(3):157-61. PubMed ID: 12365195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
    Miklya I; Knoll B; Knoll J
    Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.
    Knoll J
    CNS Drug Rev; 2001; 7(3):317-45. PubMed ID: 11607046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives.
    Shimazu S; Miklya I
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):421-7. PubMed ID: 15093948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP).
    Knoll J; Miklya I
    Life Sci; 2016 Dec; 167():32-38. PubMed ID: 27777099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
    Shimazu S; Tsunekawa H; Yoneda F; Katsuki H; Akaike A; Janowsky A
    Eur J Pharmacol; 2003 Dec; 482(1-3):9-16. PubMed ID: 14659999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enantioselective synthesis and absolute configuration of (-)-1-(benzofuran-2-yl)-2-propylaminopentane, ((-)-BPAP), a highly potent and selective catecholaminergic activity enhancer.
    Oka T; Yasusa T; Ando T; Watanabe M; Yoneda F; Ishida T; Knoll J
    Bioorg Med Chem; 2001 May; 9(5):1213-9. PubMed ID: 11377179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.